Bayer – approvals in China and the USA support growth
At Bayer, the pharmaceuticals division is giving the group a boost. On 3 November, Bayer presented its third-quarter figures. The pharmaceuticals division generated revenue of EUR 4,680 million, EBITDA before special items rose by 23.6 % to EUR 1,292 million, and the margin was 27.6 %. At the same time, the group raised its guidance. The pharmaceuticals division’s margin is expected to be 25 to 27 % in 2026, compared with the previously planned 23 to 25 %. For the group, Bayer now expects currency-adjusted EBITDA before special items of EUR 9.8 to 10.3 billion. That provides support.
The focus is on two active substances. Kerendia grew by 64.9 %, adjusted for exchange rates and portfolio changes, and exceeded the revenue mark of EUR 1 billion in the twelve months since 1 October 2025. Asundexian was approved as Sunharbo in China on 26 October and in the USA on 9 November, as an adjunct to antiplatelet therapy following a non-cardioembolic ischaemic stroke or a high-risk TIA. According to Bayer, it is the world’s first approved active substance to block coagulation factor XIa. In the OCEANIC-STROKE trial involving 12,327 patients, there were 26 % fewer ischaemic strokes than with antiplatelet therapy alone.
On 17 September, the FDA approved the extension of Kerendia’s indication to chronic kidney disease in type 1 diabetes. In the FINE-ONE trial involving 242 participants, UACR, a measure of protein excretion in urine, was 28 % lower after six months than with placebo. If Bayer succeeds in further expanding its indications, Kerendia could continue its run. What remains clear is that the bottom line is still in the red. The net result in the third quarter was minus EUR 672 million, while net financial debt stood at EUR 31.083 billion. Bayer still has to plug these holes.
Cardiol Therapeutics – A fresh and novel approach in a niche market
Cardiol Therapeutics is targeting a gap in a heart disease that is not well addressed. In the US, there is currently only one approved treatment for recurrent pericarditis: rilonacept (Arcalyst), with an annual list price of USD 302,000. Around 40,000 patients are affected. There are no approved treatments for recurrent pericarditis outside the US. CardiolRx™ is an oral medication that is in Phase III clinical development to reduce the risk of pericarditis recurrence without the risk of immune system suppression. The FDA has granted CardiolRx ™ Orphan Drug Designation for pericarditis, including its recurrent form. The company sees market potential of more than USD 1 billion. If approval is secured, this could provide a significant boost for Cardiol.
On September 23, Cardiol reported progress in the Phase III MAVERIC study. The original target of 110 patients was reached earlier than the end-of-September target previously announced. Because a blinded analysis showed fewer relapses than expected, the steering committee recommended increasing enrolment to up to 150 patients to ensure enough events are observed to support robust conclusions. The company considers the lower relapse rate encouraging. Results are now expected in mid-2027; the previous target was for the first quarter of 2027. The primary endpoint is the time to the first new recurrence, as in the pivotal trial for rilonacept.
The optimism is based on the preceding Phase II MAVERIC study, an open-label pilot trial published this year in the Journal of the American Heart Association. Among 27 patients enrolled, the pain score fell by 3.7 points by Week 8, while the median time to pain resolution/near-resolution was just 5 days. Recurrences declined from 5.8 events per year pre-study to 0.9 during treatment. Analysts’ price targets stand at USD 11 from B. Riley, USD 10 from Canaccord Genuity, USD 9 from H.C. Wainwright, USD 7.40 from First Berlin, and USD 5 from Brookline. The share is currently trading at just USD 0.96.
Novartis – experience and a full pipeline
Business is running smoothly at Novartis. On 27 October, the group presented its third-quarter figures. Revenue rose to USD 14,522 million, compared with USD 13,909 million in the previous year. Core operating income climbed to USD 6,036 million from USD 5,460 million, and the margin to 41.6 % from 39.3 %. Core earnings per share rose to USD 2.46 from USD 2.25. For 2026, Novartis now expects core operating income to remain stable or increase slightly rather than decline. Operationally, things are therefore going well.
There are two sides to the cardiovascular business. Leqvio grew by 63 % to USD 506 million in the third quarter, compared with USD 308 million in the previous year. Alongside the figures, Novartis also reported that the FDA had updated the label. Lowering LDL cholesterol is now recognised as a means of reducing major cardiovascular events in those at increased risk. By contrast, generic drugs in the USA have turned off the tap for the blockbuster Entresto. Revenue fell to USD 1,165 million from USD 1,877 million, a decline of 38 %.
However, the pipeline is providing a fresh supply. On 23 October, the six-year analysis of the NATALEE trial showed that Kisqali together with hormone therapy reduces the risk of death in early breast cancer by 19.1 %. On the same day, Novartis presented the REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing multiple sclerosis. The annualised relapse rate was 0.073 and 0.080 with remibrutinib, compared with 0.112 and 0.116 with teriflunomide. On 7 October, Rhapsido received FDA approval for symptomatic dermographism. For the anticoagulant abelacimab, which is intended to prevent strokes in atrial fibrillation, Novartis plans to submit its application in 2028. This creates breathing room for the period after Entresto.
Conclusion
Large corporations and small specialty companies are working toward the same goal, and Chicago has shown just how much is happening in this space. Bayer is advancing two active ingredients, Kerendia and Asundexian; approvals in China and the US are driving the company’s growth. Cardiol Therapeutics is approaching conclusion of the MAVERIC Phase III trial, which builds on promising Phase II data and, if successful, could fill a gap in treating recurrent pericarditis. Novartis is growing with Leqvio, has a full pipeline, and is raising its outlook, even as Entresto falters. All three companies have solid fundamentals.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a “Transaction”). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is also a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
